Parkinson’s disease (PD) is a degenerative CNS disorder of the central nervous system marked by the dysfunction and eventual loss of dopaminergic neurons that regulate movement. Despite a rapidly evolving understanding of its pathophysiology, current therapies only focus on treating symptoms of PD (tremors, bradykinesia, rigidity). A common theme that NDs share is one of neuronal insult followed by neuron death, which contributes to the decline and, in many instances, eventual death of patients. In PD this is seen with the substantial loss of dopaminergic neurons in patient brains.
Neurodon’s work combining novel molecules with cellular and animal models of neurodegeneration has shown that maintaining cellular homeostasis blocks initiation of neuronal death pathways in PD. We have demonstrated that treatment with our novel molecules improve coordination in a mouse model of PD, while maintaining brain cell mass in the substantia nigra pars compacta, the brain area affected by PD.